<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age/><report-id>ZA-ELI_LILLY_AND_COMPANY-ZA201301002968</report-id><gender>male</gender><reactions><reaction>hyperglycemia</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>HUMALOG LISPRO</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>South Africa</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734884_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151008</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>ZA-ELI_LILLY_AND_COMPANY-ZA201301002968</safetyreportid>
		<primarysourcecountry>ZA</primarysourcecountry>
		<occurcountry>ZA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-21</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-11</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-16</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>ZA-ELI_LILLY_AND_COMPANY-ZA201301002968</companynumb>
		<primarysource>
			<reportercountry>ZA</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reportercountry>ZA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>RB</patientinitial>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 1 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>hyperglycemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hyperglycemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hyperglycaemia</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121206</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20121209</reactionenddate>
				<reactionduration>4</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Blood glucose</testname>
				<testresult>&gt; 20</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>ZA</obtaindrugcountry>
				<drugbatchnumb>C012156H</drugbatchnumb>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>74</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>74 DF, qd</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-12-05</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-12-08</drugenddate>
				<drugtreatmentduration>4</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="6">Not Applicable</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>ZA</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugdosagetext>UNK, unknown</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<actiondrug code="6">Not Applicable</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hyperglycaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>who <Semaphore x="1802982" class="Disease or Finding" value="Communication Disorder" score="1.00" ID="C2958">contacted </Semaphore>the company via a <Semaphore x="2473907" class="Occupation" value="Salesperson" score="1.00" ID="C75553">sales </Semaphore>representative to report an <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event</Semaphore>, <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a male patient of unknown age and ethnicity. Additional information was provided by the <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reporter.The patient <Semaphore x="2009057" class="Procedure" value="Health Assessment Prior to Exposure" score="1.00" ID="C88067">was a reasonably well </Semaphore><Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore>type I <Semaphore x="2904422" class="MedDRA LLT" value="Diabetes mellitus" score="1.00" ID="10012601">diabetic</Semaphore>. Concomitant medications were not provided.The patient received <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>(<Semaphore x="669768" class="Medicine" value="Humalog" score="0.49" ID="228096">Humalog</Semaphore>) 74 units daily (reported as 74/26/24) via a disposable KwikPen device, beginning on 05-Dec 2012 for an unspecified indication. On 06-Dec 2012, the day after initiating <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro</Semaphore>, the patient experienced <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>with <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>sugars of <Semaphore x="1995141" class="AnatomicStructure" value="Greater Curvature of the Stomach" score="1.00" ID="C12262">greater </Semaphore>than 20 mmol/l <Semaphore x="2905796" class="MedDRA LLT" value="Diabetic ketoacidosis" score="1.00" ID="10012671">(with no diabetic ketoacidosis) </Semaphore>after using two <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>Kwikpens of lot number C012156H. Subsequently, the patient was hospitalized for <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>on an unspecified date between 06-Dec 2012 and 08-Dec 2012. At the time of the event, the patient did not have an <Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection</Semaphore>, <Semaphore x="3032386" class="MedDRA LLT" value="Infarction" score="1.00" ID="10061216">infarction</Semaphore>, <Semaphore x="2039496" class="Disease or Finding" value="Hypoglycemia" score="1.00" ID="C3126">hypoglycemia </Semaphore>and <Semaphore x="3255593" class="MedDRA LLT" value="Somogyi phenomenon" score="1.00" ID="10052093">Somogyi effect</Semaphore>, no increased <Semaphore x="2587854" class="Disease or Finding" value="Stress" score="1.00" ID="C35041">stress </Semaphore>levels and no problems with <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3040617" class="MedDRA LLT" value="Injection" score="1.00" ID="10052995">injection </Semaphore>site</Semaphore>. Initially, it was reported the patient experienced <Semaphore x="2039496" class="Disease or Finding" value="Hypoglycemia" score="1.00" ID="C3126">hypoglycemia</Semaphore>. On 08-Dec 2012, <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>was discontinued in the hospital and the <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>resolved on 09-Dec 2012. Upon follow up, it was also stated the patients <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.87" ID="269493">glucose </Semaphore>only settled into normal values with a new prefilled pen was given to the patient and <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was ongoing. Further corrective <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatments </Semaphore>and additional information regarding <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>were not provided. Date of hospital discharge was unknown.The report contained a suspect <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>prefilled disposable KwikPen device (lot number C012156H associated with <Semaphore x="3204997" class="MedDRA LLT" value="Product quality issue" score="1.00" ID="10069327">product complaint </Semaphore>2465077). The operator of the device and the training status of the patient were not reported. General device duration of use and suspect device duration of use were reported as two days. At the time of follow up, the device was being returned to the <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer </Semaphore>for evaluation.The reporting <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>related the event of <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>to <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>and the disposable KwikPen device, as the patients <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.87" ID="269493">glucose </Semaphore>only settled into normal values after initiating a new Kwikpen.Update 18-Jan 2013: Additional information was received on 16-Jan 2013 from the <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore><Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reporter. Reporter demographics were updated; medical history of <Semaphore x="2659346" class="Disease or Finding" value="Type 1 Diabetes Mellitus" score="1.00" ID="C2986">type I <Semaphore x="2904422" class="MedDRA LLT" value="Diabetes mellitus" score="1.00" ID="10012601">diabetes </Semaphore></Semaphore>added; <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.87" ID="269493">glucose </Semaphore>laboratory value was added; <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>formulation updated to prefilled disposable Kwikpen; action taken with <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>was updated to change to new pre filled pen; suspect <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="1.00" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>Kwikpen disposable device was added; event of <Semaphore x="2039496" class="Disease or Finding" value="Hypoglycemia" score="1.00" ID="C3126">hypoglycemia </Semaphore>was updated to <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia</Semaphore>; <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>causality was changed to yes; expectedness was updated for the event of <Semaphore x="2036545" class="Disease or Finding" value="Hyperglycemia" score="1.00" ID="C26797">hyperglycemia </Semaphore>and case narrative was updated to reflect additional information received.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>